Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer

Jemal, 2007, Cancer statistics, CA Cancer J. Clin., 57, 43, 10.3322/canjclin.57.1.43 Menon, 2001, Ovarian cancer screening in the general population: current status, Int. J. Gynecol. Cancer, 11, 3, 10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x Ozols, 2005, Epithelial ovarian cancer, 895 National Institutes of Health Consensus Development Panel. Ovarian cancer: screening, treatment and followup; (1994), Document Number 3. Bast, 2005, New tumor markers: CA125 and beyond, Int. J. Gynecol. Cancer, 15, 274, 10.1111/j.1525-1438.2005.00441.x Jacobs, 1999, Screening for ovarian cancer: a pilot randomized controlled trial, Lancet, 353, 1207, 10.1016/S0140-6736(98)10261-1 Prorok, 2000, Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial, Control Clin. Trials, 21, 273S, 10.1016/S0197-2456(00)00098-2 Lacey, 2006, Ovarian cancer screening in women with a family history of breast or ovarian cancer, Obstet. Gynecol., 108, 1176, 10.1097/01.AOG.0000239105.39149.d8 Menon, 2009, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Lancet Oncol., 10, 327, 10.1016/S1470-2045(09)70026-9 Helzlsouer, 1993, Prospective study of serum CA-125 levels as markers of ovarian cancer, Jama, 269, 1123, 10.1001/jama.269.9.1123 Mann, 1988, Preoperative serum CA-125 levels in patients with surgical stage i invasive ovarian adenocarcinoma, J. Natl. Cancer Inst., 80, 208, 10.1093/jnci/80.3.208 Menon, 2005, Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer, J. Clin. Oncol., 23, 7919, 10.1200/JCO.2005.01.6642 McIntosh, 2004, Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma, Gynecol. Oncol., 95, 9, 10.1016/j.ygyno.2004.07.039 Scholler, 2006, Bead-based ELISA for validation of ovarian cancer early detection markers, Clin. Cancer Res., 12, 2117, 10.1158/1078-0432.CCR-05-2007 Skates, 2004, Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions, J. Clin. Oncol., 22, 4059, 10.1200/JCO.2004.03.091 Hellstrom, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res., 63, 3695 Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res., 65, 2162, 10.1158/0008-5472.CAN-04-3924 Galgano, 2006, Jr., Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod. Pathol., 19, 847, 10.1038/modpathol.3800612 Rosen, 2005, Potential markers that complement expression of CA125 in epithelial ovarian cancer, Gynecol. Oncol., 99, 267, 10.1016/j.ygyno.2005.06.040 Shah, 2009, Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125, Cancer Epidemiol. Biomarkers Prev., 18, 1365, 10.1158/1055-9965.EPI-08-1034 Goff, 2000, Ovarian carcinoma diagnosis: results of a national ovarian cancer survey, Cancer, 89, 2068, 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z Goff, 2004, Frequency of symptoms of ovarian cancer in women presenting to primary care clinics, Jama, 291, 2705, 10.1001/jama.291.22.2705 Goff, 2007, Development of an ovarian cancer symptom index, Cancer, 109, 221, 10.1002/cncr.22371 Andersen, 2008, Combining a Symptoms Index with CA125 to improve detection of ovarian cancer, Cancer, 113, 484, 10.1002/cncr.23577 Lowe, 2008, Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer, Cancer Epidemiol. Biomarkers Prev., 17, 2480, 10.1158/1055-9965.EPI-08-0150 Scholler, 2008, Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA, Clin. Cancer Res., 14, 2647, 10.1158/1078-0432.CCR-07-1442 Havrilesky, 2008, Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence, Gynecol. Oncol., 110, 374, 10.1016/j.ygyno.2008.04.041 American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA. American Cancer Society (2008) (updated 2008 cited 2009 Aug 24) Available from, http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Pavlik, 2009, The search for meaning—symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy, Cancer, 115, 3689, 10.1002/cncr.24407